Epithelial Cell Spheroids for Personalized Ion Channel Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing ion channel modulators for channelopathies like cystic fibrosis are inefficient due to variable responses to treatments among patients with the same genotype, and existing assays do not effectively personalize drug therapies for specific mutations.
Innovation Solution
A method involving epithelial cell spheroids is used to determine ion channel responses to chemical and biological compounds by contacting spheroids with the compounds and identifying physiological responses, which can indicate how a subject would respond to the treatment, allowing for personalized treatment regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional assays are used to develop ion channel modulators, then general treatment protocols can be established, but personalized treatment efficacy cannot be determined due to variable responses among patients with the same genotype
Solution Approach 1:
The invention segments the patient population by creating individualized cell-based assays using patient-specific cells (e.g., skin fibroblasts, blood cells) that are genetically modified to express specific ion channel mutations. This allows treatment response to be tested separately for each patient or genotype group, enabling personalized medicine approaches while maintaining the ability to generalize findings across populations with the same mutation.
Solution Approach 2:
The invention changes the fundamental parameter of the assay system from using generic cell lines to using patient-specific cells with their native genetic background. This parameter change preserves the original genotype's cellular environment, allowing for accurate prediction of individual treatment responses while maintaining adaptability across different patient populations.
2Adaptability or versatility
If patient-specific assays are developed for each mutation, then personalized treatment can be achieved, but assay complexity and resource requirements increase significantly
Solution Approach 1:
The invention creates a universal assay platform that can handle multiple different ion channel mutations using the same basic methodology. The platform uses standardized procedures for cell culture, genetic modification, and drug testing that can be applied across different patient samples and mutation types, reducing overall complexity while maintaining personalized testing capability.
Solution Approach 2:
The invention creates simplified copies of patient-specific cells through genetic modification of easily obtainable cell types (like skin fibroblasts or blood cells) to express the mutation of interest. This copying approach avoids the complexity of working with primary patient tissues while preserving the genetic characteristics needed for personalized treatment prediction.
3Reliability
If traditional cell culture methods are used, then established protocols can be followed, but they do not accurately reflect in vivo ion channel function and treatment responses
Solution Approach 1:
The invention applies local quality by preserving the native genetic and cellular environment of patient-specific cells while only introducing the necessary genetic modification to express the mutation. This maintains the local cellular characteristics that determine treatment response while using standardized culture conditions, achieving both biological relevance and experimental consistency.
Data Source
AI summary
Provided are epithelial cell spheroids including spheroids that have apical membranes and cilia that face towards the interior core of the spheroid and spheroids that have apical membranes and cilia that face away from the interior core of the spheroid. Also provided methods of making and using such spheroids.